Purpose: To estimate the exchange rate of creatine (Cr) CEST and to evaluate the pH sensitivity of guanidinium (Guan) CEST in the mouse brain.
Methods: Polynomial and Lorentzian line-shape fitting (PLOF) were implemented to extract the amine, amide, and Guan CEST signals from the brain Z-spectrum at 11.7T. Wild-type (WT) and knockout mice with the guanidinoacetate N-methyltransferase deficiency (GAMT ) that have low Cr and phosphocreatine (PCr) concentrations in the brain were used to extract the CrCEST signal. To quantify the CrCEST exchange rate, a two-step Bloch-McConnell (BM) fitting was used to fit the CrCEST line-shape, B -dependent CrCEST, and the pH response with different B values. The pH in the brain cells was altered by hypercapnia to measure the pH sensitivity of GuanCEST.
Results: Comparison between the Z-spectra of WT and GAMT mice suggest that the CrCEST is between 20% and 25% of the GuanCEST in the Z-spectrum at 1.95 ppm between B = 0.8 and 2 μT. The CrCEST exchange rate was found to be around 240-480 s in the mouse brain, which is significantly lower than that in solutions (∼1000 s ). The hypercapnia study on the mouse brain revealed that CrCEST at B = 2 μT and amineCEST at B = 0.8 μT are highly sensitive to pH change in the WT mouse brain.
Conclusions: The in vivo CrCEST exchange rate is slow, and the acquisition parameters for the CrCEST should be adjusted accordingly. CrCEST is the major contribution to the opposite pH-dependence of GuanCEST signal under different conditions of B in the brain.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11054327 | PMC |
http://dx.doi.org/10.1002/mrm.29662 | DOI Listing |
Strahlenther Onkol
January 2025
Department of Radiation Oncology, University Hospital Düsseldorf, Düsseldorf, Germany.
Purpose: The aim of this review is to give an overview of the results of prospective and retrospective studies using allogenic reconstruction and postmastectomy radiotherapy (PMRT) in breast cancer and to make recommendations regarding this interdisciplinary approach.
Materials And Methods: A PubMed search was conducted to extract relevant articles from 2000 to 2024. The search was performed using the following terms: (breast cancer) AND (reconstruction OR implant OR expander) AND (radiotherapy OR radiation).
Background: Non-invasive biofluid and MRI measures of blood-brain-barrier (BBB) dysfunction may aid early detection of cerebral small vessel disease (cSVD). Plasma markers of astrocytic function and injury, such as S100 calcium-binding protein B (S100b), have gained increased attention in relation to BBB integrity and cognition. Here we explored the inter-relationships between plasma S100b levels, an MRI measure of water exchange rate across the BBB (kw), and cognitive performance among older adults.
View Article and Find Full Text PDFBackground: Magnetization transfer (MT) MRI is sensitive to the presence of macromolecules, including amyloid-beta, and previous work suggests that it may be useful for discriminating patients with Alzheimer's disease (AD) from healthy controls. In this study, we investigated if quantitative MT (qMT) is capable of detecting the amyloid concentration in a preclinical cohort.
Method: We recruited 14 subjects with a clinical dementia rating of 0 from NYU's ADRC cohort (7 male, mean age 74, 6 amyloid-negative).
Alzheimers Dement
December 2024
Central Clinical School, Monash University, Melbourne, VIC, Australia.
Background: Growing evidence shows neurovascular dysfunction occurs early in Alzheimer's disease (AD) and may be a useful early marker of pathology. Blood-brain barrier water exchange rate (BBB kw) is a novel measure of fluid transport through the neurovascular unit. Lower BBB kw has been associated with vascular risk factors, but its relationship with age, vascular brain health and biomarkers of AD remains equivocal.
View Article and Find Full Text PDFDavos Alzheimer's Collaborative Healthcare System Preparedness (DAC-SP) aims to catalyze global healthcare system transformation, providing patients with quicker access to life-changing innovations and therapies. Utilizing implementation science, the DAC-SP Early Detection flagship program launched in 2021, engaging seven healthcare systems across six countries (Brazil, Jamaica, Japan, Mexico, Scotland, and the United States). The program's primary aim was to increase the rate of early detection of cognitive impairment by integrating commercially available digital cognitive assessments (DCAs) into primary care and other non-specialty care settings.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!